Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.35 |
| ▸ | JAK3 | P52333 | 3/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10225712 | 0.86 | JAK2 (0.34) | JAK2JAK1JAK3TYK2HTR2A | |
| SCHEMBL18869770 | 0.81 | NOTUM (0.34) | JAK2JAK1JAK3TYK2HTR2A | |
| SCHEMBL10174527 | 0.74 | PTGDR2 (0.41) | JAK2JAK1JAK3TYK2HTR2A | |
| SCHEMBL5728647 | 0.73 | PTGDR2 (0.46) | HTR2APTGDR2PSMB5 | |
| SCHEMBL9167795 | 0.69 | PSMB5 (0.46) | JAK2JAK1JAK3TYK2PTGDR2 | |
| SCHEMBL2442841 | 0.68 | PTGDR2 (0.41) | PTGDR2EPHX2 | |
| SCHEMBL10776428 | 0.68 | NUDT1 (0.42) | JAK2JAK1JAK3PTGDR2PSMB5 | |
| SCHEMBL18432616 | 0.68 | JAK2 (0.32) | JAK2JAK1JAK3HTR2APSMB5 | |
| SCHEMBL10788453 | 0.67 | PSMB5 (0.44) | JAK2JAK1JAK3TYK2PTGDR2 | |
| SCHEMBL1515856 | 0.67 | PTGDR2 (0.43) | PTGDR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, P2RY10, HRH4 | JAK2 3232/4885JAK1 3189/4885JAK3 4579/4885 |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, HRH4, P2RY10 | JAK2 2867/4885JAK1 2949/4885JAK3 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.